Skip to content
MARKETS / NASDAQ / ELAB
NASDAQ · PHARMACEUTICAL PREPARATIONS

Pmgc Holdings Inc. ELAB

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$590,084
$-7.7M
$-6.4M
In brief

What this company does

PMGC Capital LLC (“PMGC Capital”) is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging, Inc. (“Pacific Sun Packaging” or “Pacific Sun”) is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology (“IT”) hardware industries. AGA Precision Systems LLC (“AGA Precision Systems” or “AGA”) is a specialized computer numerical control (“CNC”) machine shop focused on high-tolerance milling, turning, mold manufacturing, and machining of complex metals including titanium and Inconel. PMGC Holdings Inc. is a diversified holding company focused on acquiring and growing valuable assets and operating businesses across various industries.

Written from the business description in PMGC Holdings Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 590,084.00
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.6 · Net income -7.7
0.8M1.6M-4.0M2022202320242025
Compound annual growth
−8.3%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1313 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Net -1313.0%
-500%-1000%2022202320242025
ROE
FY2025 · ROE -106.9%
-50%-100%-150%2022202320242025

Each USD of equity lost 107 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -6.4
-2.5M-5.0M2022202320242025

Total assetsUSD 12.9M
EquityUSD 7.8M
CashUSD 5.4M
Current ratio1.74×

Equity funds 61% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022
Revenue $B0.0·0.00.0
Operating income $B−0.0−0.0··
EBITDA $B−0.0−0.0··
Income tax $B0.0···
Net income $B−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0·
EPS, diluted $··−0.40−0.19
Dividend / sh $····
Payout %····
ROE %−106.9−119.1−173.5−159.1
Shares out B0.000.000.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 17 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 78 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image